Press release
Neuroblastoma Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Clarity Pharma, Y mAbs Therapeutics, Nova Biopharma, Eli Lilly, Illumina, Recombio, United Therapeutics
"Neuroblastoma Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Neuroblastoma Therapeutics Market.
The report provides a detailed description of the Neuroblastoma drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Neuroblastoma Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/neuroblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Neuroblastoma Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Neuroblastoma therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuroblastoma treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Neuroblastoma drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Neuroblastoma treatment market.
Learn More about the Clinical and Commercial Development Activities in the Neuroblastoma Therapeutics Domain:
https://www.delveinsight.com/report-store/neuroblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Neuroblastoma Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Neuroblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Neuroblastoma products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Molecule Type
Neuroblastoma Products have been categorized under various Molecule types such as
• Oligonuleotide
• Peptide
• Small molecule
Request for Sample PDF to Understand More About the Neuroblastoma Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/neuroblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Neuroblastoma Therapeutics Analysis
There are approx. 35+ key companies developing therapies for Neuroblastoma. Currently, Clarity Pharmaceuticals is leading the therapeutics market with its Neuroblastoma drug candidates in the most advanced stage of clinical development.
Neuroblastoma Companies in the Therapeutics Market Include:
• Clarity Pharmaceuticals
• Y mAbs Therapeutics
• Nova Biopharma
• Eli Lilly and Company
• Illumina Radiopharmaceuticals
• Recombio
• United Therapeutics
• Molecular Insight Pharmaceuticals
• GE Healthcare
• Millennium Pharmaceuticals
• Genentech
• Actuate Therapeutics
And Many Others
Emerging and Marketed Neuroblastoma Therapies Covered in the Report Include:
• 67Cu MeCOSar Octreotate: Clarity Pharmaceuticals
• Isotretinoin: Nova Laboratories
• AK 01: Eli Lilly and Company
And Many More
Get an in-depth Assessment of the Emerging Therapies and Neuroblastoma Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/neuroblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Neuroblastoma Current Treatment Patterns
4. Neuroblastoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Neuroblastoma Late-Stage Products (Phase-III)
7. Neuroblastoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Neuroblastoma Discontinued Products
13. Neuroblastoma Product Profiles
14. Neuroblastoma Companies
15. Neuroblastoma Drugs
16. Dormant and Discontinued Products
17. Neuroblastoma Unmet Needs
18. Neuroblastoma Future Perspectives
19. Neuroblastoma Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/neuroblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
------------------------------------------------------------------------------------------------------------------------------
Healthcare Consulting and Competitive Intelligence Services by DelveInsight
Discover DelveInsight's Comprehensive Market Research and Consulting Services:
https://www.delveinsight.com/market-research
Elevate your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics, at:
https://www.delveinsight.com/medical-devices
Empowering Cancer Care: DelveInsight's oncology consulting services offer personalized guidance and cutting-edge expertise to navigate the ongoing clinical, commercial, and regulatory developments, visit for more details:
https://www.delveinsight.com/oncology
Other Trending Healthcare Reports by DelveInsight
Pulmonology Devices Market
https://www.delveinsight.com/report-store/pulmonology-devices-market
Small Cell Lung Cancer Market
https://www.delveinsight.com/report-store/small-cell-lung-cancer-market
Bronchiectasis Market
https://www.delveinsight.com/report-store/bronchiectasis-market
Lennox Gastaut Syndrome Market
https://www.delveinsight.com/report-store/lennox-gastaut-syndrome-market
Holter Monitor Market
https://www.delveinsight.com/report-store/holter-monitor-market
Muscle Invasive Bladder cancer Market
https://www.delveinsight.com/report-store/muscle-invasive-bladder-cancer-market
Osteochondrodysplasia Market
https://www.delveinsight.com/report-store/osteochondrodysplasia-market
Anesthesia Machines Market
https://www.delveinsight.com/report-store/anesthesia-workstation-machines-market
Secondary Myelofibrosis Market
https://www.delveinsight.com/report-store/secondary-myelofibrosis-market
Guillain-Barre Syndrome (GBS) Market
https://www.delveinsight.com/report-store/guillain-barre-syndrome-gbs-market
Hepatitis A Market
https://www.delveinsight.com/report-store/hepatitis-a-market
Sickle Cell Disease Market
https://www.delveinsight.com/report-store/sickle-cell-disease-market
Mucinous Cystic Neoplasms (MCNs) Market
https://www.delveinsight.com/report-store/mucinous-cystic-neoplasms-mcns-market
Overt Hepatic Encephalopathy Market
https://www.delveinsight.com/report-store/overt-hepatic-encephalopathy-market
Familial Hypercholesterolemia Market
https://www.delveinsight.com/report-store/familial-hypercholesterolemia-market-report
Lateral Epicondylitis (Tennis Elbow) Disease Market
https://www.delveinsight.com/report-store/lateral-epicondylitis-tennis-elbow-disease-market
Diverticulitis Market
https://www.delveinsight.com/report-store/diverticulitis-market
Crows Feet Market
https://www.delveinsight.com/report-store/crows-feet-market
Helicobacter Pylori Infections Market
https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market
Charcot-Marie-Tooth Disease Market
https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
Neurovascular Thrombectomy Devices Market
https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
Neurothrombectomy Devices Market
https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
Stargardt Disease (STGD) Market
https://www.delveinsight.com/report-store/stargardt-disease-stgd-market
Venous Leg Ulcer Market
https://www.delveinsight.com/report-store/venous-leg-ulcer-market
Genital Herpes Market
https://www.delveinsight.com/report-store/genital-herpes-market-forecast
Idiopathic Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/idiopathic-thrombocytopenic-purpura-market
Morquio Syndrome Market
https://www.delveinsight.com/report-store/morquio-syndrome-market
Lymphoedema Market
https://www.delveinsight.com/report-store/lymphoedema-market
Neurotrophic Keratopathy Market
https://www.delveinsight.com/report-store/neurotrophic-keratopathy-market
Oncolytic Virus Cancer Therapy Market
https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market
Orthostatic Hypotension Market
https://www.delveinsight.com/report-store/orthostatic-hypotension-market
Advanced Wound Care (AWC) Market
https://www.delveinsight.com/report-store/advanced-wound-care-market
Opioid-related Disorders Market
https://www.delveinsight.com/report-store/opioid-related-disorders-market
Ankylosing Spondylitis (AS) Market
https://www.delveinsight.com/report-store/ankylosing-spondylitis-as-market
Chronic Insomnia Market
https://www.delveinsight.com/report-store/chronic-insomnia-market
Microscopic Polyangiitis (MPA) Market
https://www.delveinsight.com/report-store/microscopic-polyangiitis-mpa-market
Esophageal Squamous Carcinoma Market
https://www.delveinsight.com/report-store/esophageal-squamous-carcinoma-market
Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market
Chemotherapy Induced Neutropenia (CIN) Market
https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market
Idiopathic Interstitial Pneumonia Market
https://www.delveinsight.com/report-store/idiopathic-interstitial-pneumonia-market
Diphtheria Market
https://www.delveinsight.com/report-store/diphtheria-market
Dyslipidemia Market
https://www.delveinsight.com/report-store/dyslipidemia-market
Thymus Cancer Market
https://www.delveinsight.com/report-store/thymus-cancer-market
Tendonitis Market
https://www.delveinsight.com/report-store/tendonitis-market
Alpha-Antitrypsin Deficiency Market
https://www.delveinsight.com/report-store/alpha-antitrypsin-deficiency-market
Factor XA Inhibitor Market
https://www.delveinsight.com/report-store/factor-xa-inhibitor-market
Undifferentiated Pleomorphic Sarcoma Market
https://www.delveinsight.com/report-store/undifferentiated-pleomorphic-sarcoma-market
Carcinoid Tumor Syndrome Market
https://www.delveinsight.com/report-store/carcinoid-tumor-syndrome-market
Primary Progressive Multiple Sclerosis (PPMS) Market
https://www.delveinsight.com/report-store/primary-progressive-multiple-sclerosis-ppms-market
Thalassemia Market
https://www.delveinsight.com/report-store/thalassemia-market
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neuroblastoma Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Clarity Pharma, Y mAbs Therapeutics, Nova Biopharma, Eli Lilly, Illumina, Recombio, United Therapeutics here
News-ID: 3186345 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Neuroblastoma
Neuroblastoma Market Massive Growth opportunity Ahead
Neuroblastoma market Size, Status, and Forecast for the 2025-2034. In-depth research has been compiled to provide the most up-to-date information on key aspects of the worldwide market. This research report covers major aspects of the Neuroblastoma Market including drivers, restraints, historical and current trends, regulatory scenarios, and technological advancements. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The…
Neuroblastoma Clinical Pipeline | 20+ Companies Advancing the Future of Treatmen …
The Neuroblastoma market is rapidly evolving with cutting-edge research and breakthrough therapies driven by leading companies like United Therapeutics, EUSA Pharma, Y-mAbs Therapeutics, and Clarity Pharmaceuticals. These innovators are revolutionizing treatment approaches and shaping the future of Neuroblastoma care, offering new hope for patients worldwide.
DelveInsight's 'Neuroblastoma Pipeline Insight 2025' report provides comprehensive global coverage of pipeline Neuroblastoma therapies in various stages of clinical development. Major pharmaceutical companies are working to…
Pediatric Neuroblastoma Treatment Market - Redefining Possibilities: Advancement …
Newark, New Castle, USA: The "Pediatric Neuroblastoma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Pediatric Neuroblastoma Treatment Market: https://www.growthplusreports.com/report/pediatric-neuroblastoma-treatment-market/7681
This latest report researches the industry structure,…
Neuroblastoma Treatment Market Projected to Garner Significant Revenues by 2024
Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. The cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is listed as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. The cancer is most prevalent in infants…
Neuroblastoma Drugs Market Size, Share, Development by 2024
New report published by Global Info Research which offers insights on the Global Neuroblastoma Drugs market.
Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently starts from one of the adrenal glands, but can also develop in the neck, chest, abdomen, or spine. Symptoms may include bone pain, a lump in the abdomen, neck, or chest, or a painless bluish lump under…
Global Neuroblastoma Treatment Market: Latest Trends and Insights 2023
Neuroblastoma is the most common type of cancer in infants. The cancer is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. The cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is listed as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. The cancer is most prevalent in infants…
